MicroRNA expression profiling in Imatinib-resistant Chronic Myeloid Leukemia patients without clinically significant ABL1-mutations

The development of Imatinib Mesylate (IM), the first specific inhibitor of BCR-ABL1, has had a major impact in patients with Chronic Myeloid Leukemia (CML), establishing IM as the standard therapy for CML. Despite the clinical success obtained with the use of IM, primary resistance to IM and molecul...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: San José-Enériz, Edurne, Román-Gómez, José, Jiménez-Velasco, Antonio, Garate, Leire, Martin, Vanesa, Cordeu, Lucia, Vilas-Zornoza, Amaia, Rodríguez-Otero, Paula, José Calasanz, María, Prósper, Felipe, Agirre, Xabier
Formato: Artigo
Idioma:Inglês
Publicado: BioMed Central 2009
Assuntos:
Short Communication
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC2743636/
https://ncbi.nlm.nih.gov/pubmed/19723306
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1476-4598-8-69
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares